| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $30,900 | 1 | 100 |
Sells | $0 | 0 | 0 |
| PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 1 | $30,900 | 0 | $0 | $30,900 |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Cue Biopharma, Inc. have bought $30,900 and sold $0 worth of Cue Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Cue Biopharma, Inc. have bought $992,458 and sold $855,550 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) — $30,900.
The last purchase of 30,000 shares for transaction amount of $30,900 was made by PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) on 2024‑12‑16.
| 2024-12-16 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 30,000 0.0473% | $1.03 | $30,900 | -23.04% | ||
| 2023-08-25 | Suri Anish | PRESIDENT AND CSO | 4,000 0.0088% | $2.76 | $11,040 | -27.78% | ||
| 2023-08-14 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 3,000 0.0065% | $2.86 | $8,580 | -33.06% | ||
| 2023-03-23 | Sale | Kiener Peter A | director | 9,325 0.0208% | $3.28 | $30,586 | -14.24% | |
| 2022-05-27 | Morich Frank | 28,000 0.0769% | $3.75 | $105,000 | -19.17% | |||
| 2022-05-23 | Fletcher Aaron G.L. | 55,000 0.1455% | $3.34 | $183,700 | -12.61% | |||
| 2022-03-31 | Fletcher Aaron G.L. | 735,000 2.0277% | $4.76 | $3.5M | -36.07% | |||
| 2021-11-16 | Sale | Kiener Peter A | director | 1,361 0.0046% | $18.02 | $24,525 | -77.86% | |
| 2021-11-15 | Sale | Suri Anish | President and CSO | 8,000 0.0257% | $18.05 | $144,400 | -78.74% | |
| 2021-11-15 | Sale | Kiener Peter A | director | 18,815 0.0599% | $17.92 | $337,165 | -78.74% | |
| 2021-11-11 | Sale | Suri Anish | President and CSO | 20,000 0.0634% | $15.07 | $301,354 | -74.37% | |
| 2021-10-01 | Sale | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | 1,251 0.0039% | $14.21 | $17,783 | -66.60% | |
| 2021-09-24 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 3,400 0.011% | $14.72 | $50,051 | -65.45% | ||
| 2021-09-23 | Sale | Suri Anish | PRESIDENT AND CSO | 20,000 0.0648% | $15.23 | $304,646 | -66.40% | |
| 2021-03-16 | Sale | Pienta Kenneth | Chief Medical Officer | 439 0.0015% | $15.09 | $6,626 | -19.03% | |
| 2021-03-15 | Sale | Pienta Kenneth | Chief Medical Officer | 13,000 0.0427% | $15.10 | $196,269 | -20.52% | |
| 2021-02-17 | Sale | Pienta Kenneth | Chief Medical Officer | 4,274 0.0142% | $15.05 | $64,345 | -17.94% | |
| 2021-02-16 | Sale | Pienta Kenneth | Chief Medical Officer | 16,000 0.0525% | $15.15 | $242,422 | -19.24% | |
| 2021-01-20 | Sale | Pienta Kenneth | Chief Medical Officer | 2,720 0.0093% | $15.07 | $40,980 | -13.79% | |
| 2021-01-20 | Pienta Kenneth | Chief Medical Officer | 5,440 0.0187% | $15.07 | $81,959 | -13.79% |
| PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 164578 0.209% | $91,011.63 | 7 | 0 | <0.0001% |
| Fletcher Aaron G.L. | 940000 1.1938% | $519,820.00 | 4 | 0 | <0.0001% | |
| Gray Cameron | director | 677500 0.8605% | $374,657.50 | 2 | 0 | <0.0001% |
| Suri Anish | PRESIDENT AND CSO | 135638 0.1723% | $75,007.81 | 2 | 6 | +22.99% |
| DIGIANDOMENICO ANTHONY | director | 57000 0.0724% | $31,521.00 | 5 | 0 | +68.36% |
| Morich Frank | 28000 0.0356% | $15,484.00 | 1 | 0 | <0.0001% | |
| Sandercock Colin | SVP, General Counsel and Sec | 17125 0.0217% | $9,470.13 | 3 | 3 | +52.57% |
| Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | 10472 0.0133% | $5,791.02 | 1 | 1 | <0.0001% |
| Pienta Kenneth | Chief Medical Officer | 2000 0.0025% | $1,106.00 | 2 | 5 | +385.96% |
| Kiener Peter A | director | 357 0.0005% | $197.42 | 0 | 3 | |
| MARLETT CHRISTOPHER A | director | 0 0% | $0 | 9 | 6 | +65.21% |
$5,197,510 | 107 | -35.99% | $44.44M | |
$1,695,621 | 55 | 17.90% | $47.13M | |
$448,545 | 49 | -21.85% | $39.62M | |
Cue Biopharma, Inc. (CUE) | $6,787,959 | 35 | 49.84% | $43.54M |
$711,440 | 26 | 20.43% | $42.95M | |
$523,320 | 24 | 94.37% | $45.71M | |
$241,165 | 22 | -16.72% | $44.61M | |
$26,736,140 | 20 | -18.64% | $43.78M | |
$1,044,754 | 13 | -23.07% | $42.18M | |
$19,300,035 | 11 | 45.88% | $45.77M | |
$31,978,951 | 10 | -70.03% | $38.9M | |
$4,895,542 | 8 | -11.85% | $42.96M | |
$32,684,649 | 8 | -15.84% | $46.22M | |
$8,470,804 | 6 | -13.28% | $47.46M | |
$32,007,657 | 4 | -45.65% | $45.25M | |
$157,740 | 3 | 153.95% | $40.31M | |
$49,127 | 3 | -42.90% | $43.35M | |
$12,498 | 2 | 39.61% | $42.66M | |
$150,000 | 1 | 5.48% | $42.17M |
| Increased Positions | 14 | +23.73% | 1M | +6.16% |
| Decreased Positions | 18 | -30.51% | 359,785 | -2.08% |
| New Positions | 9 | New | 752,578 | New |
| Sold Out Positions | 4 | Sold Out | 41,162 | Sold Out |
| Total Postitions | 55 | -6.78% | 18M | +4.08% |
| Bleichroeder Lp | $4,296.00 | 8.63% | 6.82M | 0 | 0% | 2025-09-30 |
| Gc Wealth Management Ria, Llc | $2,162.00 | 4.34% | 3.43M | +100,000 | +3% | 2025-09-30 |
| Vanguard Group Inc | $1,915.00 | 3.85% | 3.04M | -148,024 | -4.64% | 2025-09-30 |
| Geode Capital Management, Llc | $504.00 | 1.01% | 800,768 | +108,595 | +15.69% | 2025-09-30 |
| Boothbay Fund Management, Llc | $385.00 | 0.77% | 610,964 | +610,964 | New | 2025-09-30 |
| Robertson Stephens Wealth Management, Llc | $301.00 | 0.61% | 478,500 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $283.00 | 0.57% | 449,162 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $204.00 | 0.41% | 324,521 | -63 | -0.02% | 2025-09-30 |
| Advisory Research Inc | $162.00 | 0.33% | 257,225 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $143.00 | 0.29% | 227,064 | +93,600 | +70.13% | 2025-09-30 |